Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,652 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,652 shares of Natera stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total value of $335,091.68. Following the completion of the transaction, the insider owned 140,643 shares of the company’s stock, valued at approximately $28,528,026.12. The trade was a 1.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total value of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.

Natera Stock Up 5.3%

Shares of NTRA traded up $10.83 during mid-day trading on Thursday, hitting $213.94. The stock had a trading volume of 1,861,579 shares, compared to its average volume of 1,650,189. The company has a market cap of $30.64 billion, a PE ratio of -131.25 and a beta of 1.57. The company’s fifty day simple moving average is $201.85 and its two-hundred day simple moving average is $215.63. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same period in the prior year, the company earned ($0.41) earnings per share. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on NTRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Piper Sandler reaffirmed an “overweight” rating and set a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. BTIG Research reduced their price objective on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Wells Fargo & Company boosted their price objective on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Morgan Stanley cut their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.60.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Horizon Investments LLC grew its holdings in shares of Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the last quarter. Sound Income Strategies LLC grew its holdings in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the last quarter. Savvy Advisors Inc. grew its holdings in shares of Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares during the last quarter. Finally, First Horizon Corp grew its holdings in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.